JAJane V. Aldrich

Jane V. Aldrich

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jane V. Aldrich has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas F. Murray

    Creighton University School of Medicine 2500 California Plaza, Omaha, NE 68178 U.S.A.

    9 shared publications
  • Jay P. McLaughlin

    ‡Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987

    6 shared publications
  • H. Choi

    Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, USA

    3 shared publications
  • Kshitij A. Patkar

    Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, 66045

    3 shared publications
  • Nicolette C. Ross

    ‡Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL 34987

    3 shared publications
  • T.F. Murray

    Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, USA

    3 shared publications

Latest Publications

  • Alanine analogues of [D‐Trp]CJ‐15,208: novel opioid activity profiles and prevention of drug‐ and stress‐induced reinstatement of cocaine‐seeking behaviour

    by J V Aldrich, S N Senadheera, N C Ross, K A Reilley, M L Ganno, S E Eans, T F Murray, J P McLaughlin

    Background and Purpose: The novel macrocyclic peptidecyclo[Phe‐D‐Pro‐Phe‐D‐Trp] ([D‐Trp]CJ‐15,208) exhibits κ opioid (KOP) receptor antagonist activity in bothin vitroandin vivoassays. The four alanine analogues of this peptide were synthesized and characterized bothin vitroandin vivoto assess the contribution of different amino acid residues to the activity of [D‐Trp]CJ‐15,208.Experimental Approach: The peptides were synthesized by a combination of solid phase peptide synthesis and cyclization in solution. The analogues were evaluatedin vitroin receptor binding and functional assays, andin vivowith mice using a tail‐withdrawal assay for antinociceptive and opioid antagonist activity. Mice demonstrating extinction of cocaine conditioned‐place preference (CPP) were pretreated with selected analogues to evaluate prevention of stress or cocaine‐induced reinstatement ofCPP.Key Results: The alanine analogues displayed pharmacological profilesin vivodistinctly different from [D‐Trp]CJ‐15,208. While the analogues exhibited varying opioid receptor affinities and κ and μ opioid receptor antagonist activityin vitro, they produced potent opioid receptor‐mediated antinociception (ED50= 0.28–4.19 nmol, i.c.v.)in vivo. Three of the analogues also displayedKOPreceptor antagonist activityin vivo. Pretreatment with an analogue exhibiting bothKOPreceptor agonist and antagonist activityin vivoprevented both cocaine‐ and stress‐induced reinstatement of cocaine‐seeking behaviour in theCPPassay in a time‐dependent manner.Conclusions and Implications: These unusual macrocyclic peptides exhibitin vivoopioid activity profiles different from the parent compound and represent novel compounds for potential development as therapeutics for drug abuse and possibly as analgesics.


  • Open Access

    Zyklophin, a short-acting kappa opioid antagonist, induces scratching in mice

    by K.M. DiMattio, T.V. Yakovleva, J.V. Aldrich, A. Cowan, L.Y. Liu-Chen


  • The Macrocyclic Peptide Natural Product CJ-15,208 Is Orally Active and Prevents Reinstatement of Extinguished Cocaine-Seeking Behavior

    by Jane V. Aldrich, Sanjeewa N. Senadheera, Nicolette C. Ross, Michelle L. Ganno, Shainnel O. Eans, Jay P. McLaughlin

    The macrocyclic tetrapeptide natural product CJ-15,208 (cyclo[Phe-d-Pro-Phe-Trp]) exhibited both dose-dependent antinociception and kappa opioid receptor (KOR) antagonist activity after oral administration. CJ-15,208 antagonized a centrally administered KOR selective agonist, providing strong evidence it crosses the blood–brain barrier to reach KOR in the CNS. Orally administered CJ-15,208 also prevented both cocaine- and stress-induced reinstatement of extinguished cocaine-seeking behavior in the conditioned place preference assay in a time- and dose-dependent manner. Thus, CJ-15,208 is a promising lead compound with a unique activity profile for potential development, particularly as a therapeutic to prevent relapse to drug-seeking behavior in abstinent subjects.


  • Analytical and Biological Methods for Probing the Blood-Brain Barrier

    by Courtney D. Kuhnline Sloan, Pradyot Nandi, Thomas H. Linz, Jane V. Aldrich, Kenneth L. Audus, Susan M. Lunte

    The blood-brain barrier (BBB) is an important interface between the peripheral and central nervous systems. It protects the brain against the infiltration of harmful substances and regulates the permeation of beneficial endogenous substances from the blood into the extracellular fluid of the brain. It can also present a major obstacle in the development of drugs that are targeted for the central nervous system. Several methods have been developed to investigate the transport and metabolism of drugs, peptides, and endogenous compounds at the BBB. In vivo methods include intravenous injection, brain perfusion, positron emission tomography, and microdialysis sampling. Researchers have also developed in vitro cell-culture models that can be employed to investigate transport and metabolism at the BBB without the complication of systemic involvement. All these methods require sensitive and selective analytical methods to monitor the transport and metabolism of the compounds of interest at the BBB.


  • Open Access

    Opioid peptides: potential for drug development

    by Jane V. Aldrich, Jay P. McLaughlin


  • Unexpected Opioid Activity Profiles of Analogues of the Novel Peptide Kappa Opioid Receptor Ligand CJ‐15,208

    by Jane V. Aldrich, Santosh S. Kulkarni, Sanjeewa N. Senadheera, Nicolette C. Ross, Kate J. Reilley, Shainnel O. Eans, Michelle L. Ganno, Thomas F. Murray, Jay P. McLaughlin

    An alanine scan was performed on the novel κ opioid receptor (KOR) peptide ligand CJ‐15,208 to determine which residues contribute to the potent in vivo agonist activity observed for the parent peptide. These cyclic tetrapeptides were synthesized by a combination of solid‐phase peptide synthesis of the linear precursors, followed by cyclization in solution. Like the parent peptide, each of the analogues exhibited agonist activity and KOR antagonist activity in an antinociceptive assay in vivo. Unlike the parent peptide, the agonist activity of the potent analogues was mediated predominantly, if not exclusively, by μ opioid receptors (MOR). Thus analogues 2 and 4, in which one of the phenylalanine residues was replaced by alanine, exhibited both potent MOR agonist activity and KOR antagonist activity in vivo. These peptides represent novel lead compounds for the development of peptide‐based opioid analgesics.


  • Deletion of Ac‐NMePhe1 from [NMePhe1]arodyn under acidic conditions, part 2: Effects of cleavage conditions and N‐terminal functionality

    by Wei‐Jie Fang, Marco A. Bennett, Jane V. Aldrich

    Peptides containing N‐methylamino acids can exhibit improved pharmacodynamic and pharmacokinetic profiles compared to nonmethylated peptides, and therefore interest in these N‐methylated peptides has been increasing in recent years. Arodyn (Ac[Phe1,2,3,Arg4,D‐Ala8]Dyn A(1–11)NH2) is an acetylated dynorphin A (Dyn A) analog that is a potent and selective κ opioid receptor antagonist (Bennett et al., J Med Chem 2002, 45, 5617), and its analog [NMePhe1]arodyn shows even higher affinity and selectivity for κ opioid receptors (Bennett et al., J Pept Res 2005, 65, 322). During the synthesis of [NMePhe1]arodyn analogs, the arodyn‐(2–11) derivatives were obtained as major products. Analysis indicated that Ac‐NMePhe was lost from the completed peptide sequence during acidic cleavage of the peptides from the resin and that the acetyl group played an important role in this side reaction. Different cleavage conditions were evaluated to minimize this side reaction and maximize the yield of pure [NMePhe1]arodyn analogs. Modifications to the N‐terminus of the peptides to prevent the side reaction were also explored. The incorporation of a heteroatom‐containing group such as methoxycarbonyl as the N‐terminal functionality prevented this side reaction, while the incorporation of a bulky acyl group could not. Substituting NMePhe with the conformationally constrained analog Tic (1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylic acid) also prevented the side reaction. © 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 97–102, 2011.


  • Deletion of Ac‐NMePhe1from [NMePhe1]arodyn under acidic conditions, part 2: Effects of substitutions on pharmacological activity

    by Wei‐Jie Fang, Marco A. Bennett, Thomas F. Murray, Jane V. Aldrich

    Arodyn (Ac[Phe1,2,3,Arg4,D‐Ala8]Dyn A(1–11)NH2) is an acetylated dynorphin A (Dyn A) analog that is a potent and selective κ opioid receptor antagonist (Bennett et al., J Med Chem 2002, 45, 5617), and its analog [NMePhe1]arodyn shows even higher affinity and selectivity for κ opioid receptors (Bennett et al., J Pept Res 2005, 65, 322). However, the latter compound is prone to deletion of the Ac‐NMePhe moiety from the N‐terminus of the peptide during acidic cleavage as described in the accompanying paper. Several stable analogs of [NMePhe1]arodyn and [NMePhe1,Trp3]arodyn where the acetyl group was substituted with a heteroatom‐containing group were evaluated for their opioid receptor affinity, selectivity, and efficacy. Methoxycarbonyl derivatives exhibited the highest κ opioid receptor affinity among the analogs. Additional [CH3OCO‐NMePhe1]arodyn analogs where position 3 was substituted with other aromatic or nonaromatic residues were also evaluated for κ receptor affinity, selectivity, and efficacy. [CH3OCO‐NMePhe1]arodyn has similar κ opioid receptor affinity as [NMePhe1]arodyn, retains high κ opioid receptor selectivity, and is a potent κ opioid receptor antagonist. © 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 103–110, 2011.


  • A convenient approach to synthesizing peptide C‐terminal N‐alkyl amides

    by Wei‐Jie Fang, Tatyana Yakovleva, Jane V. Aldrich

    Peptide C‐terminal N‐alkyl amides have gained more attention over the past decade due to their biological properties, including improved pharmacokinetic and pharmacodynamic profiles. However, the synthesis of this type of peptide on solid phase by current available methods can be challenging. Here we report a convenient method to synthesize peptide C‐terminal N‐alkyl amides using the well‐known Fukuyama N‐alkylation reaction on a standard resin commonly used for the synthesis of peptide C‐terminal primary amides, the peptide amide linker‐polyethylene glycol‐polystyrene (PAL‐PEG‐PS) resin. The alkylation and oNBS deprotection were conducted under basic conditions and were therefore compatible with this acid labile resin. The alkylation reaction was very efficient on this resin with a number of different alkyl iodides or bromides, and the synthesis of model enkephalin N‐alkyl amide analogs using this method gave consistently high yields and purities, demonstrating the applicability of this methodology. The synthesis of N‐alkyl amides was more difficult on a Rink amide resin, especially the coupling of the first amino acid to the N‐alkyl amine, resulting in lower yields for loading the first amino acid onto the resin. This method can be widely applied in the synthesis of peptide N‐alkyl amides. © 2011 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 715–722, 2011.


  • Open Access

    Synthesis of CJ-15,208, a novel κ-opioid receptor antagonist

    by Nicolette C. Ross, Santosh S. Kulkarni, Jay P. McLaughlin, Jane V. Aldrich